A New Class of Medicines through DNA Editing
暂无分享,去创建一个
[1] Luigi Naldini,et al. Preclinical modeling highlights the therapeutic potential of hematopoietic stem cell gene editing for correction of SCID-X1 , 2017, Science Translational Medicine.
[2] A. Waldman,et al. Capture of DNA sequences at double-strand breaks in mammalian chromosomes. , 2001, Genetics.
[3] Sruthi Mantri,et al. CRISPR/Cas9 β-globin gene targeting in human haematopoietic stem cells , 2016, Nature.
[4] Richard L. Frock,et al. Ectopic expression of RAD52 and dn53BP1 improves homology-directed repair during CRISPR–Cas9 genome editing , 2017, Nature Biomedical Engineering.
[5] Sruthi Mantri,et al. Identification of Pre-Existing Adaptive Immunity to Cas9 Proteins in Humans , 2018 .
[6] Matthew C. Canver,et al. BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis , 2015, Nature.
[7] Jennifer A. Doudna,et al. Enhanced proofreading governs CRISPR-Cas9 targeting accuracy , 2017, Nature.
[8] P. Rouet,et al. Expression of a site-specific endonuclease stimulates homologous recombination in mammalian cells. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[9] M. Porteus,et al. Generation of an HIV resistant T-cell line by targeted "stacking" of restriction factors. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.
[10] R. Kucherlapati,et al. Insertion of DNA sequences into the human chromosomal β-globin locus by homologous recombination , 1985, Nature.
[11] R. Dolmetsch,et al. p 53 inhibits CRISPR – Cas 9 engineering in human pluripotent stem cells , 2018 .
[12] E. Lander,et al. Development and Applications of CRISPR-Cas9 for Genome Engineering , 2014, Cell.
[13] David J. Rawlings,et al. Tracking genome engineering outcome at individual DNA breakpoints , 2011, Nature Methods.
[14] Richard L. Frock,et al. Ectopic expression of RAD 52 and dn 53 BP 1 improves homology-directed repair during CRISPR – Cas 9 genome editing , 2017 .
[15] M. Bétermier,et al. Is Non-Homologous End-Joining Really an Inherently Error-Prone Process? , 2014, PLoS genetics.
[16] J. Hoeijmakers,et al. Molecular mechanisms of DNA double strand break repair. , 1998, Trends in cell biology.
[17] Hao Yin,et al. Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype , 2014, Nature Biotechnology.
[18] J. Corn,et al. CRISPR-Cas9 genome editing in human cells works via the Fanconi Anemia pathway , 2017, bioRxiv.
[19] E. Haddad,et al. Targeted gene addition to human mesenchymal stromal cells as a cell-based plasma-soluble protein delivery platform. , 2010, Cytotherapy.
[20] R. Barrangou,et al. CRISPR/Cas, the Immune System of Bacteria and Archaea , 2010, Science.
[21] E. Lander,et al. Development and Applications of CRISPR-Cas 9 for Genome Engineering , 2015 .
[22] S. West,et al. Double-strand break repair in human cells. , 2000, Cold Spring Harbor symposia on quantitative biology.
[23] A. Scharenberg,et al. Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template , 2015, Science Translational Medicine.
[24] Alessandro Romanel,et al. A highly specific SpCas9 variant is identified by in vivo screening in yeast , 2018, Nature Biotechnology.
[25] D. Durocher,et al. Inhibition of 53BP1 favors homology-dependent DNA repair and increases CRISPR-Cas9 genome-editing efficiency , 2017, Nature Biotechnology.
[26] Y. Doyon,et al. In vivo genome editing of the albumin locus as a platform for protein replacement therapy. , 2015, Blood.
[27] Edward M. Callaway,et al. In vivo genome editing via CRISPR/Cas9 mediated homology-independent targeted integration , 2016, Nature.
[28] George M. Church,et al. In vivo gene editing in dystrophic mouse muscle and muscle stem cells , 2016, Science.
[29] M. Porteus,et al. Human SMC 5 / 6 complex promotes sister chromatid homologous recombination by recruiting the SMC 1 / 3 cohesin complex to double-strand breaks , 2006 .
[30] B. Dujon,et al. Induction of homologous recombination in mammalian chromosomes by using the I-SceI system of Saccharomyces cerevisiae , 1995, Molecular and cellular biology.
[31] Dana Carroll,et al. Enhancing Gene Targeting with Designed Zinc Finger Nucleases , 2003, Science.
[32] J. Joung,et al. Defining and improving the genome-wide specificities of CRISPR–Cas9 nucleases , 2016, Nature Reviews Genetics.
[33] Israel Steinfeld,et al. Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells , 2015, Nature Biotechnology.
[34] M. Porteus,et al. Genome Editing: A New Approach to Human Therapeutics. , 2016, Annual review of pharmacology and toxicology.
[35] M. Porteus,et al. Human SMC5/6 complex promotes sister chromatid homologous recombination by recruiting the SMC1/3 cohesin complex to double‐strand breaks , 2006, The EMBO journal.
[36] Yang Yang,et al. A dual AAV system enables the Cas9-mediated correction of a metabolic liver disease in newborn mice , 2016, Nature Biotechnology.
[37] D. Russell,et al. Human gene targeting by viral vectors , 1998, Nature Genetics.
[38] P. Rouet,et al. Introduction of double-strand breaks into the genome of mouse cells by expression of a rare-cutting endonuclease. , 1994, Molecular and cellular biology.
[39] Wei-Ting Hwang,et al. Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. , 2014, The New England journal of medicine.
[40] Dana Carroll,et al. Genome engineering with targetable nucleases. , 2014, Annual review of biochemistry.
[41] David Baltimore,et al. Chimeric Nucleases Stimulate Gene Targeting in Human Cells , 2003, Science.
[42] Margherita Neri,et al. Site-specific integration and tailoring of cassette design for sustainable gene transfer , 2011, Nature Methods.
[43] Philippe Horvath,et al. A decade of discovery: CRISPR functions and applications , 2017, Nature Microbiology.
[44] J. Orange,et al. Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases , 2008, Nature Biotechnology.
[45] Mithat Gönen,et al. Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection , 2017, Nature.
[46] Andreas Reinisch,et al. Multiplexed genetic engineering of human hematopoietic stem and progenitor cells using CRISPR/Cas9 and AAV6 , 2017, eLife.
[47] J. Doudna,et al. The new frontier of genome engineering with CRISPR-Cas9 , 2014, Science.
[48] Gang Bao,et al. Quantifying genome-editing outcomes at endogenous loci with SMRT sequencing. , 2014, Cell reports.
[49] Tetsushi Sakuma,et al. Microhomology-mediated end-joining-dependent integration of donor DNA in cells and animals using TALENs and CRISPR/Cas9 , 2014, Nature Communications.
[50] Dongsheng Duan,et al. In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy , 2016, Science.
[51] Gang Bao,et al. A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human haematopoietic stem and progenitor cells , 2018, Nature Medicine.
[52] Aymeric Duclert,et al. Multiplex Genome-Edited T-cell Manufacturing Platform for "Off-the-Shelf" Adoptive T-cell Immunotherapies. , 2015, Cancer research.
[53] John A Zaia,et al. Preclinical development and qualification of ZFN-mediated CCR5 disruption in human hematopoietic stem/progenitor cells , 2016, Molecular therapy. Methods & clinical development.
[54] Dana Carroll,et al. Targeted chromosomal cleavage and mutagenesis in Drosophila using zinc-finger nucleases. , 2002, Genetics.
[55] John M. Shelton,et al. Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy , 2016, Science.
[56] H. Volk,et al. High prevalence of S. pyogenes Cas9-specific T cell sensitization within the adult human population – A balanced effector/regulatory T cell response , 2018, bioRxiv.
[57] Gregory McAllister,et al. p53 inhibits CRISPR–Cas9 engineering in human pluripotent stem cells , 2018, Nature Medicine.
[58] Dana Carroll,et al. Selection-free genome editing of the sickle mutation in human adult hematopoietic stem/progenitor cells , 2016, Science Translational Medicine.
[59] Ashley Williams,et al. Genome Editing and Human Reproduction: Social and Ethical Issues , 2018 .
[60] R. Bak,et al. CRISPR/Cas9 genome editing in human hematopoietic stem cells , 2018, Nature Protocols.
[61] Jeffrey C. Miller,et al. Highly efficient endogenous human gene correction using designed zinc-finger nucleases , 2005, Nature.
[62] Adrian J. Thrasher,et al. Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells , 2017, Science Translational Medicine.
[63] M. Porteus,et al. Genome Editing of Mouse Fibroblasts by Homologous Recombination for Sustained Secretion of PDGF-B and Augmentation of Wound Healing , 2014, Plastic and reconstructive surgery.
[64] David R. Liu,et al. Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage , 2016, Nature.
[65] Shondra M Pruett-Miller,et al. High-frequency genome editing using ssDNA oligonucleotides with zinc-finger nucleases , 2011, Nature Methods.
[66] Changyu Wang,et al. TALEN-mediated targeting of HPV oncogenes ameliorates HPV-related cervical malignancy. , 2015, The Journal of clinical investigation.
[67] Jennifer A. Doudna,et al. Enhanced proofreading governs CRISPR-Cas9 targeting accuracy , 2017, Nature.
[68] David Cyranoski,et al. CRISPR gene-editing tested in a person for the first time , 2016, Nature.
[69] Hojun Li,et al. In vivo genome editing restores hemostasis in a mouse model of hemophilia , 2011, Nature.
[70] Srinivasan Chandrasegaran,et al. Zinc finger nucleases: custom-designed molecular scissors for genome engineering of plant and mammalian cells , 2005, Nucleic acids research.
[71] Israel Steinfeld,et al. Global Transcriptional Response to CRISPR/Cas9-AAV6-Based Genome Editing in CD34+ Hematopoietic Stem and Progenitor Cells. , 2018, Molecular therapy : the journal of the American Society of Gene Therapy.
[72] P. Glazer,et al. Peptide Nucleic Acids as a Tool for Site-Specific Gene Editing , 2018, Molecules.
[73] Vanessa Taupin,et al. Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo , 2010, Nature Biotechnology.
[74] H. Ochs,et al. Targeted gene editing restores regulated CD40L function in X-linked hyper-IgM syndrome. , 2016, Blood.
[75] Dana Carroll,et al. Gene targeting using zinc finger nucleases , 2005, Nature Biotechnology.